Scholarlink

<p>The combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has improved clinical outcomes in advanced renal cell carcinoma (aRCC), though therapeutic resistance remains a major challenge. We conducted single-cell transcriptomic analysis on 61 tumor samples from 34 aRCC patients treated with TKIs alone or in combination with ICIs. Non-responders exhibited increased neutrophil infiltration and enrichment of SAA<sup>+</sup> tumor cells following treatment. We identified a VEGFA<sup>+</sup>CEACAM1<sup>+</sup> neutrophil subset exhibiting immunosuppressive properties that is associated with poor clinical response. In vivo, pharmacologic inhibition of SAA enhanced sensitivity to ICI plus TKI combination therapy, while blockade of the CEACAM1–TIM-3 axis in humanized PD-1 mouse models significantly potentiated anti–PD-1 efficacy. Our study establishes a single-cell atlas of the aRCC tumor microenvironment under treatment pressure and identifies a previously unrecognized SAA–CEACAM1–TIM-3 axis driving drug resistance, highlighting potential targets to improve therapy efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Liangyou Gu,
  • Qi Zhang,
  • Qiyang Liang,
  • Cheng Peng,
  • Yaohui Wang,
  • Chenfeng Wang,
  • Zhuoran Li,
  • Yezhen Tan,
  • Yanming Zhou,
  • Qing Bi,
  • Xiubin Li,
  • Jin Luo,
  • Qingbo Huang,
  • Yan Huang,
  • Xu Zhang,
  • Xin Ma,
  • Weimin Ci,
  • Baojun Wang

摘要

The combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has improved clinical outcomes in advanced renal cell carcinoma (aRCC), though therapeutic resistance remains a major challenge. We conducted single-cell transcriptomic analysis on 61 tumor samples from 34 aRCC patients treated with TKIs alone or in combination with ICIs. Non-responders exhibited increased neutrophil infiltration and enrichment of SAA+ tumor cells following treatment. We identified a VEGFA+CEACAM1+ neutrophil subset exhibiting immunosuppressive properties that is associated with poor clinical response. In vivo, pharmacologic inhibition of SAA enhanced sensitivity to ICI plus TKI combination therapy, while blockade of the CEACAM1–TIM-3 axis in humanized PD-1 mouse models significantly potentiated anti–PD-1 efficacy. Our study establishes a single-cell atlas of the aRCC tumor microenvironment under treatment pressure and identifies a previously unrecognized SAA–CEACAM1–TIM-3 axis driving drug resistance, highlighting potential targets to improve therapy efficacy.